Stifel lowered the firm’s price target on Agilon Health to $9 from $10 and keeps a Hold rating on the shares ahead of the company reporting Q4 earnings on Tuesday, February 27. The firm previously downgraded Agilon to a Hold due to longer-term structural issues with margins and a near-term lack of visibility on claims, which could continue to weigh on results, though it could become more constructive on the story if there is more clarity on both of these issues, the analyst says in a preview note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AGL:
- Agilon Health Announces CMO Transition and Interim Appointment
- Agilon Health says Benjamin Kornitzer to transition from role as CMO
- Agilon Health price target lowered to $11 from $23 at RBC Capital
- Agilon Health price target lowered to $16 from $20 at BofA
- Agilon Health price target lowered to $13 from $22 at Benchmark
